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Reactive oxygen specieAge-related neurodegenerative diseases are associated with mild impairment of oxidative metabolism and
accumulation of abnormal proteins.Within the cell, themitochondria appears to be a dominant site for initiation
and propagation of disease processes. Shifts in metabolism in response to mild metabolic perturbations may
decrease the threshold for irreversible injury in response to ordinarily sublethal metabolic insults. Mild
impairment of metabolism accrue from and lead to increased reactive oxygen species (ROS). Increased ROS
change cell signaling via post-transcriptional and transcriptional changes. The cause and consequences of mild
impairment of mitochondrial metabolism is one focus of this review. Many experiments in tissues from humans
support the notion that oxidative modiﬁcation of the α-ketoglutarate dehydrogenase complex (KGDHC)
compromisesneuronal energymetabolismandenhancesROSproduction inAlzheimer'sDisease (AD). Thesedata
suggest that cognitive decline in AD derives from the selective tricarboxylic acid (TCA) cycle abnormalities. By
contrast inHuntington's Disease (HD), amovement disorderwith cognitive features distinct formAD, complex II
+III abnormalities may dominate. These distinct mitochondrial abnormalities culminate in oxidative stress,
energy dysfunction, and aberrant homeostasis of cytosolic calcium. Cytosolic calcium, elevations even only
transiently, leads to hyperactivity of a number of enzymes. One calcium-activated enzyme with demonstrated
pathophysiological import in HD and AD is transglutaminase (TGase). TGase is a crosslinking enzymes that can
modulate transcription, inactivate metabolic enzymes, and cause aggregation of critical proteins. Recent data
indicate that TGase can silence expressionof genes involved in compensating formetabolic stress. Altogether, our
results suggest that increasing KGDHC via inhibition of TGase or via a host of other strategies to be described
would be effective therapeutic approaches in age-associated neurodegenerative diseases.
© 2009 Elsevier B.V. All rights reserved.1. Diminished metabolism, oxidative stress and increased
Transglutaminase (TGASE) are common to neurodegenerative
diseases
Huntington's disease (HD), Parkinson's disease (PD) and Alzhei-
mer's disease (AD) are age-related diseases of diverse etiologies and
pathologies, but abnormal mitochondrial function is common to all.
All cases of Huntington disease (HD) are caused by an expansion in
the polyglutamine region of the protein huntingtin (htt). HD is one of
several adult-onset neurodegenerative diseases that are caused byyloid precursor protein; Aβ,
enase complex; ETC, electron
se; MPTP, 1-methyl-4-phenyl-
; PD, Parkinson's disease; PSP,
cies; TGase, transglutaminase;
on).
ll rights reserved.genes with expanded CAG triplet repeats within their coding regions
and extended polyglutamine (Q) domains within the expressed
proteins. How these mutations produce the clinical and pathological
changes of the diseases is unknown. Mitochondrial abnormalities
occur in autopsy brain samples [1] and animal models using the
mitochondrial poisons malonate and 3-nitroproprionic acid (3NP)
mimic human HD [2]. In PD, identiﬁcation of the rare speciﬁc gene
mutations that cause PD has reinforced the relevance of oxidative
stress and mitochondrial dysfunction in the disease. The proteins that
are associated with familial PD–PTEN-induced putative kinase 1
(PINK1), DJ-1,α-synuclein, leucine-rich repeat kinase 2, and, possibly,
parkin–are either mitochondrial proteins or are associated with
mitochondria, and all interface with the pathways of oxidative stress
and free radical damage [3–5]. Animal models using the mitochon-
drial poison 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mimic human PD [6]. In AD, the rare gene mutations in amyloid
precursor protein (APP) or presenilin proteins lead to increased
production of amyloid β peptide (Aβ), which depressesmitochondrial
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stress and generally impairing metabolism. Pathological analysis and
studies of peripheral tissues demonstrate these are common features
of non-genetic forms of AD as well. The brains from patients with all
age-related neurodegenerative diseases show extensive damage from
oxidative stress in their brains at autopsy.
Reduced metabolism can be readily related to the clinical char-
acteristics of neurodegenerative diseases. The relation of mitochon-
drial changes to clinical symptoms is particularly well documented in
AD. Diminished glucose metabolism always accompanies AD and the
reduction occurs at early stages of the disease, even pre-symptom-
atically. The decline in glucose metabolism with AD was shown in
some of the earliest imaging studies of the human brain and has been
recognized for many decades. The reduction in glucose metabolism is
feasibly linked by robustly documented mechanisms to the decline in
mental function, and diminished memory is particularly vulnerable.
The sensitivity of memory to altered glucose metabolism may be
because of the close link of metabolism and neurotransmitters that
are known to involved in memory, particularly acetylcholine [7]. In
patients with APOE4 genotype that will be at greater risk to get AD
later in their life, the decline precedes the clinical characteristics by
decades [8]. Furthermore, mildly cognitively impaired patients that
have a reduction in brain glucose metabolism all go on to develop AD
[9–11]. Reductions in cerebral metabolism sufﬁcient to impair
cognition in normal individuals occur in AD. The degree of clinical
disability in AD correlates well with the magnitude of the reduction in
brain metabolism.
The question is no longer whether changes occur in mitochondria
in neurodegenerative disease. Currently, the interesting questions are
what is the cause andwhether thesemild changes inmetabolism have
any consequence on mitochondria or their ability to adapt to meta-
bolic insults and if reversal of them can be beneﬁcial to cells, animals
or patients.
Damage from free radicals is common in brains from patients with
age-related neurodegenerative disorders. Reactive oxygen species
(ROS) are normally signaling molecules. For example, they regulate
tricarboxylic acid (TCA) cycle enzymes such as KGDHC, and many
transcription factors. However, if the level is too high they will dam-
age multiple proteins. The sources of free radicals in neurons and
other cells has been reviewed recently [12,13]. Changes in antioxidant
enzymes or in key enzymes of glucose catabolism, especially those in
the mitochondria, can lead to excess radical production. Evidence for
free radical damage is extensive in brain. For example, immunostains
for reactive aldehydes or peroxynititrite reveal that the damage
caused by oxidative stress in AD brain is more extensive than are
plaques and tangles (the deﬁning feature of AD) [14]. Evidence of free
radicals (i.e., isoprostanes) can even be observed in AD and PD urine,
and these can distinguish AD and PD [15]. Increased levels of F2
isoprostane levels occur in plasma and urine of AD, but not PD patients
[16]. Although the evidence for abnormal ROS in AD, PD and HD is
overwhelming, the source of these ROS is not established.
In animal models of AD plaque formation, the changes in free
radicals precede plaque formation. Levels of plasma, urinary and brain
homogenate 8,12-iso-iPF(2alpha)-VI isoprostanes are higher in
Tg2576 than in control animals as early as 8 months of age. In con-
trast, a surge of Aβ 1–40 and 1–42 levels as well as Aβ deposits in
Tg2576 mouse brains does not occur until 12 months of age. This
suggests that brain oxidative damage contributes to AD pathogenesis
before Aβ accumulation in the AD brain [15].
Increased oxidative stress also occurs in PD [6], HD [17] and PSP
[18]. The questions in these diseases are similar to those for AD. The
evidence for oxidative damage is overwhelming but the source of the
ROS and their pathological importance is unknown. Amongst the
possibilities are mitochondria, NADPH-oxidase, iNOS xanthine oxi-
dase, monoamine oxidase and the dehydrogenase complexes such as
KGDHC. The strategies for understanding the therapeutic implicationsare similar in these diseases although the pathologies vary. Although
the underlying basis of these changes in oxidation may be primary,
determining what they are has proven elusive so the strategy has
been to target downstream consequences.
2. Reductions in key mitochondrial enzymes underlie the
reduction in glucose metabolism in neurodegenerative diseases
The simplest explanation for a reduction in metabolism is decline
in the activity of metabolic enzymes. The reductions in the α-
ketoglutarate dehydrogenase complex (KGDHC) activity in AD brain
have been particularly well documented, and the reductions appear to
be a common feature of neurodegeneration of various kinds. The
initial studies [19] that showed this decrease in AD have been widely
replicated [20–22], and there are no contravening reports. The
severity of change and their correlation with the clinical dementia
rating score vary with APOE4 genotype [23], but positive correlations
occur whether or not patients carry any APOE4 allele. Reductions in
KGDHC occur in PD [24], HD [2,18] and progressive supranuclear palsy
[18]. The reduction in KGDHC is not limited to the areas of pathology
and neuron death. The precise chemical nature of the changes in
KGDHC that lead to diminished activity in brains from AD patients are
unknown. Results suggest that the decline is a post-translational
modiﬁcation. Although the activity is diminished in all forms of AD,
the immunoreactivity is selectively altered in familial AD. In patients
bearing the APP670/671 mutation the immunoreactivity of E1k and
E2k are diminished whereas E3 is normal [25]. The reduced activity
with normal subunit protein immunoreactivity is also found in PD
[24] and progressive supranuclear palsy [18]. KGDHC activity was also
reduced in putamen from patients with HD [2].
The reductions in KGDHC activities do not reﬂect general
mitochondrial changes since some TCA cycle enzymes decline while
others increase. Brains were from patients with autopsy-conﬁrmed
AD who had also had recent clinical dementia ratings (CDR) before
death. Signiﬁcant (pb0.01) decreases occur in the activities of the
enzymes in the ﬁrst part of the TCA cycle that are combined dehydro-
genases and decarboxylases: the pyruvate dehydrogenase complex
(−41%), isocitrate dehydrogenase (−27%), and KGDHC (−57%). On
the other hand, activities of the dehydrogenases in the second half of
the TCA cycle increase: succinate dehydrogenase (complex II)
(+44%) and malate dehydrogenase (+54%) (pb0.01). Activities of
the other four TCA cycle enzymes are unchanged. All of the changes in
TCA cycle activities correlate with the clinical state (pb0.01),
suggesting a coordinated mitochondrial alteration. The highest
correlation is with pyruvate dehydrogenase complex (r=0.77) [26].
The results are consistent with a decline in these enzymes underlying
the reduction in glucose metabolism, which is coupled to the clinical
state of the patient. If we understood why the reductions occur,
treatmentsmight be devised to reactivate them and hopefully thereby
to restore brain metabolism. The relation of the changes in the TCA
cycle enzymes to TGase and oxidative stress is discussed below.
Aβ is present in mitochondria and directly effects KGDHC and
PDHC. Intracellular Aβ is present in mitochondria from brains of
transgenic mice with targeted neuronal over-expression of mutant
human APP and AD patients [27]. Aβ progressively accumulates in
mitochondria and is associated with diminished enzymatic activity of
respiratory chain complexes (III and IV) and a reduction in the rate of
oxygen consumption. Mitochondria-associated Aβ was detected as
early as 4 months, before extensive extracellular Aβ deposits [28].
Within the mitochondria Aβ will inhibit PDHC and KGDHC [29].
3. Oxidative stress can lead to the AD-like changes in the TCA cycle
The increased oxidative stress in brains from patients that died
with neurodegenerative disease and the reduction in KGDHC are
likely to be related. KGDHC is very sensitive to oxidants. Inhibition
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oxide, peroxynitrite, chloroamine [30], hypochlorite [30], hydro-
xynonenal, hyperoxia, and acrolein [31]. Overproduction of mono-
amine oxidase produces increased ROS in cells and inactivates KGDHC
[32]. Similarly, if oxidants are overproduced by knocking out SOD, ROS
increases and KGDHC is inactivated [33].
Peroxynitrite inhibits puriﬁed KGDHC in a dose- and time-
dependent manner. Loss of enzymatic activity is associated with
reduced immunoreactivity of E1k and E2k subunits, but not E3, and
increased immunoreactivity of each component to a nitrotyrosine
antibody, suggesting nitration of a tyrosine residues. Nitrosylationwas
further conﬁrmed by a combination of trypsin digestion and nano-LC-
MS/MS analysis. Tyrosine residue 556 is nitrated in the E1k subunit,
while no nitration is found in E2k and E3. Addition of GSH after
peroxynitrite treatment of KGDHC completely restores the KGDHC
activity and the immunoreactivity of E1k and E2k subunits. The
immunoreactivity of nitrotyrosine is diminished to near control level
upon addition of GSH. Such decreased immunoreactivity suggests that
nitrotyrosine of KGDHC is further modiﬁed by possibly converting –
NO2 to –NH2 in tyrosine residues to form aminotyrosine, or denitrating
–NO2 in tyrosine residues. Taken together, the data directly demon-
strate the nitration of tyrosine residue of KGDHC. The ﬁndings indicate
that the similar modiﬁcations of KGDHC may also occur in cultured
cells, and regulation of KGDHC activity by these processes may be of
signiﬁcance in AD pathology as well as in normal regulation of KGDHC
activity [34].
In addition, KGDHC can be inactivated by other means. KGDHC is
very sensitive to other toxins such as cisplastin [35], MPTP [36], and 3-
NP. In addition, KGDHC can be inactivated by transglutaminase [37].
4. Transglutaminase (TGase) is elevated in multiple
neurodegenerative diseases
TGase catalyzes a covalent bond between peptide-bound gluta-
mine residues and either lysine-bound peptide residues or mono- or
polyamines (Fig. 1). Multiple lines of evidence suggest that TGase is
involved in neurodegenerative diseases including frontotemporal
dementia, AD, progressive supranuclear palsy (PSP), HD, and PD [38].
Transcription of TGase is increased by head trauma and stroke and
glutamate toxicity and by hypoxia [39] . In age-related neurodegen-
erative diseases TGase enzyme activity is increased in selectively
vulnerable brain regions, TGase proteins are associated with inclusion
bodies characteristic of the diseases, and prominent proteins in theFig. 1. Transglutaminase (TGase) is elevated in Alzheimer's disease and expanded CAG-
disorders.inclusion bodies are modiﬁed by TGase enzymes including tau, alpha-
synuclein, and huntingtin protein. Evidence for N(epsilon)-(gamma-
L-glutamyl)-L-lysine (GGEL) linkages is apparent in brain and CSF
samples from AD and HD patients [40–42]. Four gamma-glutamylpoly
amines are present in normal human CSF. All four gamma-glutamy-
lamines are elevated in HD CSF. These ﬁndings support the suggestion
that gamma-glutamylpolyamines are reﬂective of TGase activity in
human brain, that polyamination is an important post-translational
modiﬁcation of brain proteins, and that TGase-catalyzed modiﬁcation
of proteins is increased in HD brain [42]. Thus, a wide range of studies
suggest that activation and/or increased transcription of TGase could
have wide ranging effects and serve as a therapeutic target.
5. Increased TGase can alter metabolism by translational and
post-translational changes
As described in the introduction, TGase is increased in multiple
neurodegenerative diseases and in animal and chemical treatments
that model these diseases. In contrast to its inactivating effect on TCA
cycle enzymes, oxidative stress can upregulate TGase. For example,
oxidative stress appears important in glutamate-evoked TGase
upregulation in astrocyte cultures [43]. Glutamate causes a dose-
dependent increase in ROS production. Pre-incubation with glutathi-
one ethyl ester or cysteamine recovers oxidative status and reduces
glutamate-increased tissue TGase. Thus, TGase up-regulation may be
part of a biochemical response to oxidative stress [43]. An increase of
TGase 2 expression may contribute to activation of microglia. After
activation of BV-2 microglial cell lines by lipopolysaccharide, the
expression of TGase 2 and iNOS increase in parallel. Furthermore,
TGase inhibition reduces secretion of NO by up to 80%, in a dose-
dependent manner. This observation suggests that TGase 2 controls
iNOS transcription or iNOS message stability [44].
Results in cells and with isolated enzyme support a role for TGase
in neurodegenerative diseases and as a possible cause of the decline in
metabolism in neurodegenerative disorders. By its ability to crosslink,
TGase can inhibit enzymes such as glyceraldehyde-3-phosphate de-
hydrogenase, KGDHC [45] or aconitase [46], key enzymes of glycolysis
and the TCA cycle. The crosslinks with aconitase have been observed
in HD brains at autopsy [46], and most of the mitochondrial aconitase
in HD caudate is present as high-Mr aggregates. Aconitase activity is
markedly decreased in HD caudate (a region severely damaged by the
disease) [47,48] and HD transgenic mice [49,50]. These ﬁndings
suggest that an increase of TGase activity in HD caudate may con-
tribute to mitochondrial dysfunction by incorporating aconitase into
inactive polymers [46]. Although KGDHC is also a substrate for TGase
[37], that linkage has not been shown in brains from patients that died
with neurodegenerative diseases. TGase action on transcription may
be due to crosslinking of transcription factors to diminish gene
cascades that may normally enhance mitochondrial biogenesis or
function [51]. For the inactivation of mitochondrial enzymes to occur
under physiological or pathological conditions, TGasemust be present
in the mitochondria and appropriate substrates must be present.
Studies reveal that TGase is present in mitochondria from both brain
and liver [52]. However, the levels are very low.
Studies that diminish TGase activity in vivo support the suggestion
that TGase is pathologically important. Studies in TGase knockout
mice [53] as well with the TGase inhibitor cystamine [54,55] suggest
TGase activation is a critical part of the HD disease process. Under-
standing the mechanism for that neuroprotection is important for
designing better therapeutic approaches.
TGase is a multifunctional enzyme that may have beneﬁcial effects.
TGase is up-regulated in neurons exposed to oxygen and glucose
deprivation and increased TGase expression protects neurons against
oxygen and glucose deprivation induced cell death independent of its
transamidating activity. TGase protects by interacting with HIF1 [56].
TGase attenuates the HIF1 hypoxic response pathway, and up-
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indicate that TGase may play an important role in protecting against
the delayed neuronal cell death in ischemia and stroke [56].
TGase can also affect mitochondrial function by acting at the level
of transcription. Accumulating data suggests that the elevated TGase
in neurodegenerative conditions may impair transcription and the
ability to adapt. This implies that blocking TGase should promote
transcription and be protective. Convincing evidence for this scenario
has emerged in studies of HD. Transcriptional repression may be
responsible for the inability of mutant huntingtin (mhtt) expressing
cells to cope with the metabolic stress. Multiple groups have shown
that mhtt is able to sequester needed transcription factors and other
proteins necessary for transcription initiation. TGase, like mhtt, has
been shown to alter speciﬁc transcription factors (e.g., Sp1) [57,58].
The transcription factor(s) found to be modiﬁed by TGase play a role
in the expression of nuclear-encoded mitochondrial proteins such as
cytochrome c and PGC-1α (PPARγ-coactivator 1). Numerous meta-
bolic proteins are repressed in HD models and HD patients [59–61].
These proteins [including cytochrome c (cyt c) and PGC-1α] are under
the control of nuclear transcription factors that contain glutamine
(Q)-rich activation domains. Since the large number of Q residues in
these activation domains provides a possible target for modiﬁcation
by TGase, experiments tested the ability of TGase to repress the
transcription of metabolic genes (cyt c and PGC-1a) that are down-
regulated in HD models and patients. Transient transfection of a
promoter/reporter of cyt c reveals a basal decrease in the cyt c
promoter activity between htt and mhtt expressing cells exposed to
serum starvation/restimulation. Co-transfection of TGase greatly
reduces cyt c promoter activity. Pharmacological inhibition, as well
as genetic deletion of TGase, induces cyt c promoter activity and
increases mRNA levels of cyt c and PGC-1α. Citrate synthase activity,
the ﬁrst step of the TCA cycle, also increases after TGase inhibition [51]
Whether the action of TGase on transcription factors is a physiological
regulatory mechanism that goes wrong if mutant huntingtin is pre-
sent remains to be determined.
If the decreased ability of mutant huntingtin cells to respond to
metabolic stress is due transcriptional repression and diminished
mitochondrial activity, then increased expression of nuclear-encoded
mitochondrial proteins (such as cytochrome c) should enhance mito-
chondrial biogenesis and increase survival ofmutanthuntingtin (mhtt)-
encoding neurons. If the inability of mhtt-expressing cells to respond to
energetic stress is due the over-activity of the enzyme TGase that has
been reported in HD patients and models alike, then inhibiting TGase
should increase mitogenesis and be neuroprotective. Immortalized
murine striatal neurons frommicewith ahuntingtin genewith a normal
numberof repeats aswell as a separate strainwith apathological level of
repeats were used to test whether TGase inhibitors can be neuropro-
tective. Inhibition of TGase increases the transcription of keymitochon-
drial proteins in cells expressing mutant huntingtin. Thus, over-active
TGase within mhtt-expressing cells may silence the expression of
nuclear-encoded mitochondrial proteins through the modiﬁcation of
transcription factors, and loss of this compensatory mechanism causes
these cells to be more susceptible to the metabolic stress that is seen in
HD [51]. The cells expressing mutant huntingtin are more sensitive to
themitochondrial toxin, 3-NP, which induces HD like changes in animal
models. 3-NP acts by inhibiting complex II in the mitochondrial
respiratory chain. To test whether TGase inhibition can prevent
neuronal death due to mitochondrial dysfunction, the role of the
TGase inhibitor ZDON and its inactive control in preventing death were
tested. ZDON, but not its analog, enters the cell and inhibits TGase [51].
ZDON is neuroprotective, but the inactive analog is not in both striatal
cell lines with mutant huntingtin and in myoblasts from HD patients.
Theneuroprotective efﬁcacyof ZDONcorrelateswith its ability to inhibit
TGase.
Themechanism(s) bywhich TGase promotes harmful effects in HD
remain(s) under study. TGase can act directly at gene promoters suchas PGC-1α (a coactivator) and cytochrome c to repress the ability of
transcription factors to recruit the basal transcription factor machin-
ery. TGase is bound to a complex of proteins that interact directly with
the promoters of these target genes. Inhibition of TGase activity using
pharmacological inhibitors or RNAi knockdown leads to increased
promoter activity, mRNA levels and protein levels of the transcription
factor PGC1α and the protein cytochrome c. Finally, pharmacological
inhibition of TGase activity leads to robust protection of HD cell lines
as well as primary neurons and HD myoblasts against the mitochon-
drial toxicant, 3-NP. Together these studies suggest that transgluta-
minase inhibition overcomes mitochondrial dysfunction in HD by
facilitating the expression of genes involved in mitochondrial
biogenesis and function [62].
6. The α-ketoglutarate dehydrogenase complex (KGDHC) is a
calcium sensitive central enzyme of metabolism that produces
and is controlled by ROS
A compelling body of evidence indicates that KGDHC is one of the
important targets of mitochondrial injury. An understanding of the
multiple roles of KGDHC [63] is required to identify the upstream (i.e.,
causes) and downstream (i.e., consequences) effects which may
provide additional therapeutic targets. KGDHC catalyses the reaction
α−Ketoglutarate + CoASH+NADþYSuccinyl−CoA + CO2 +NADH
The substrates and the products of this reaction are central to
several key metabolic and signaling pathways (see Fig. 2).
The α-ketoglutarate decarboxylase subunit (E1) catalyses the
rate–limiting stage of the overall KGDHC reaction [64]. In brain
mitochondria, the activity of KGDHC is the lowest of the TCA cycle
enzymes and may be rate limiting for overall TCA cycle activity in vivo
[65,66]. Consequently, the KGDHC reaction is essential for sustaining
mitochondrial oxidative energy metabolism and neuronal viability
(Fig. 3).
Mammalian KGDHC is an integral mitochondrial enzyme tightly
bound to the inner mitochondrial membrane on the matrix side [67].
It binds speciﬁcally to Complex I of the mitochondrial respiratory
chain [68] and may form a part of the TCA enzyme super-complex
[69]. Structurally, KGDHC is composed of multiple copies of three
enzymes: α-ketoglutarate dehydrogenase (E1k subunit, EC 1.2.4.2),
dihydrolipoamide succinyltransferase (E2k subunit, EC 2.3.1.12), and
lipoamide dehydrogenase (E3 subunit, EC 1.6.4.3). The E3 subunit of
KGDHC is identical to that of pyruvate dehydrogenase; it is also
known as dihydrolipoamide dehydrogenase (Dld). The other subunits
are unique to KGDHC. All the subunits are encoded by nuclear genes.
For enzymatic activity, E1k requires the cofactor thiamine pyrophos-
phate, which is tightly bound; E2k requires covalently bound
dihydrolipoic acid; and E3 requires covalently bound ﬂavin [70–72].
The composition of KGDHC and its content exhibit tissue
speciﬁcity. Neurons are particularly enriched in KGDHC compared to
glia [73]. Immunogold electron microscopy with an antibody against
the E1k component of the KGDHC demonstrates that KGDHC is
heterogeneously distributed in mitochondria within individual astro-
cytes originating either from cerebellum or cerebral cortex [74]. Brain
E1k appears to differ from heart. In the heart complex, only the known
E1k is found. However, in brain the band corresponding to the brain
E1k component includes a novel E1k protein. The functional
competence of the novel brain isoenzyme and different regulation
of E1k and E1kl by 2-oxoglutarate are apparent from kinetic studies
[75]. Brain KGDHC also differs from the heart KGDHC in the ratio to
the other components, lower apparentmolecularmass and stability of
isolated complex.
In addition to its traditional role to produce NADH in the TCA cycle,
KGDHC performs another uniquely important function by providing
succinyl-CoA for heme synthesis which is initiated in mitochondria
Fig. 2. Role of KGDHC in brain metabolism.
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(ETC) and several antioxidant enzymes protecting the brain from
oxidative stress.
Alternative functions are known for each of the KGDHC subunits.
Conditions that destabilize the E3 homodimer enabled themouse, pig,
or human enzyme to function as a protease [78]. A truncated gene
product (MIRTD) of E2k contributes to the biogenesis of the mito-
chondrial respiratory complexes [79]. E3 has diaphorase activity,
being able to catalyze the oxidation of NADH to NAD by using different
electron acceptors such as O2, labile ferric iron [80], nitric oxide [81],
and ubiquinone [82,83]. In this capacity, E3 would primarily have a
prooxidant role, achieved by reducing O2 to a superoxide radical or
ferric to ferrous iron. However, the ability to scavenge nitric oxide and
to reduce ubiquinone to ubiquinol suggests that the diaphorase
activity of E3 may also have an antioxidant role [81–83].
The regulation of KGDHC activity is rather complex and apparently
makes it an integrating hub for cellular Ca2+, metabolite, and ROS
signaling systems. KGDHC is activated by low concentrations of Ca2+
and matrix ADP, and is inhibited by high NADH and its own product,
succinyl–CoA [84–88]. In addition to this classical regulation, new
data emerge that KGHDC activity is both controlled by and controls
the intracellular ROS levels. Several studies have shown that KGDHC
can produce free radicals at E2k and H2O2 at E3. These become
physiologically signiﬁcant when the NAD+/NADH ratio in the
mitochondrial matrix is low (i.e., under reducing conditions)
[89,90]. This production appears to be pathologically importantFig. 3. Subunit composition of KGDHC. KGDHC produces oxidants or NADsince inhibitors of KGDHC can protect against in vitro associated
with over-production of ROS, such as ischemia [91,92] and glutamate
toxicity [93] while also blocking production of free radicals.
Excessive entry of calcium accompanies many cell injuries and
mitochondria buffer rapid increases in calcium in neurons and most
other cells. The role of calcium in activation of KGDHC has been
reviewed in [94]. Mitochondria isolated from adult rat cerebral cortex
and cerebellum generate extremely reactive hydroxyl radicals, plus
ascorbyl and other carbon-centered radicals when exposed to 2.5 μM
Ca2+, 14 mM Na+, plus elevated ADP under normoxic conditions,
circumstances that prevail in the cytoplasm of neurons during
excitotoxin-induced neurodegeneration [95]. In heart, the calcium
that enters the mitochondria following stimulation activates both
PDHC and KGDHC [84,85,88]. KGDHC is more sensitive than PDHC to
calcium [88].
The sensitivity of the KGDHC to oxidants may also be regulatory.
For example, H2O2 is known to diminish NADH production by inacti-
vating the KGDHC [32,89], whereas its E2k component can sense the
intramitochondrial redox state which affects the E2k dihydrolipoate/
lipoate ratio [96]. It has also been shown that thyil radicals can inhibit
E1k and KGDHC, and thyil radicals formed at E2k lipoate residues can
interact with thioredoxin [96,97]. Although arguable in light of yet
insufﬁcient evidence, the ramiﬁcation of this is that KGDHCmay serve
as a major regulatory element adjusting the metabolic output of TCA
cycle according to the redox state of intramitochondrial thiols,
pyridine nucleotides, and ROS production.H depending on redox state. Low NAD+ promotes ROS formation.
127G.E. Gibson et al. / Biochimica et Biophysica Acta 1802 (2010) 122–1347. Consequences of mild impairment of KGDHC
Energy failure may be a late event following inhibition of KGDHC.
α-Keto-β-methylvalerate (KMV), a structural analogue of α-ketoglu-
tarate has reasonable speciﬁcity but low potency [65]. KMV inhibits
acetylcholine synthesis before impairing energy metabolism as mea-
sured by ATP levels [65]. KMV promotes translocation of mitochon-
drial cytochrome c to the cytosol, and leads to activation of caspase-3
before the mitochondrial membrane potential or ROS production is
altered. Thus, the results suggest a decrease in KGDHC activity induces
gene cell death cascades before energetic failure. This suggests that
treatments that affect these gene cascades may be effective in neuro-
degenerative diseases that are accompanied by mild impairment of
oxidative metabolism.
Succinylphosphonte (SP) and its esters are potent and speciﬁc
KGDHC inhibitors. SP and its phosphonoethyl (PESP) and carbox-
yethyl (CESP) esters at a concentration of 0.01 mM completely inhibit
isolated KGDHC. In cells, 0.01 mM SP, PESP, or CESP inhibit KGDHC by
70%. The diethyl- and tri-ethyl esters were also inhibitory in the cell
system, but only after preincubation, suggesting the release of their
charged groups by cellular esterases. Thus, SP and its monoethyl
esters target cellular KGDHC directly, while the di- and triethyl esters
are activated in intact cells. When tested on other enzymes that bind
α-ketoglutarate or relatedα-keto acids, SP has minimal effects and its
two esters (CESP and TESP) are ineffective even at concentrations one
order of magnitude higher than those that inhibit cellular KGDHC
activity. The high speciﬁcity in targeting KGDHC, penetration into
cells, and minimal transformation by cellular enzymes indicates the
usefulness of these compounds for studies of reduced KGDHC activity
on neuronal and brain function [98].
Mild impairment of KGDHC by SP-esters alters the metabolic
proﬁle of intact cerebellar granule cells during incubation with [1-13C]
glucose and [U-13C]glutamate. The results suggest increased α-
ketoglutarate formation, increased transamination of α-ketoglutarate
with valine, leucine, and GABA, and a new equilibrium position of the
aspartate aminotransferase reaction. Overall, the ﬁndings also suggest
that some carbon derived from alpha-ketoglutarate may bypass the
block in the TCA cycle at KGDHC by means of the GABA shunt and/or
conversion of valine to succinate. The results are consistent with the
suggestion that impairing KGDHC increases the GABA shunt in order
to maintain normal metabolism [99]. The shift in metabolism may
make the cells less able to adapt to further insults.
Similar effects on metabolism were observed in cells by changing
KGDHC activities by genetic manipulation of E2k. As described above,
the KGDHC complex consists of three enzymes: E1k, E2k and E3. Any
one of the three can be manipulated genetically to examine the con-
sequences of a reduction in KGDHC activity. The results are com-
plicated, but made more revealing, by the observation that manipu-
lating each subunit does not necessarily have a parallel effect on the
activity of KGDHC. Human embryonic kidney (HEK) cells were stably
transfected with an E2k sense or antisense expression vector. Sense
control (E2k-mRNA-100) was comparedwith two clones in which the
mRNA was reduced to 67% of control (E2k-mRNA-67) or to 30% of
control (E2k-mRNA-30). The levels of the E2k protein in clones
paralleled the reduction in mRNA, and E3 proteins are not altered.
Unexpectedly, the clone with the greatest reduction in E2k protein
(E2k-mRNA-30) has a 40% increase in E1k protein. The activity of the
complex was only 52% of normal in E2k-mRNA-67 clone, but was near
normal (90%) in E2k-mRNA-30 clone [100].
Subsequent experiments testedwhether a reduction in the KGDHC
activity would alter cellular metabolism by comparing metabolism of
[U-13C]glucose in cell line (E2k100) to one in which the KGDHC
activity was about 70% of control (E2k67). After incubation of the cells
with [U-13C]glucose, the E2k67 cells showed a greater increase in 13C
labeling of alanine and lactate compared to the E2k100 cells, which
suggests an increase in glycolysis. Increased GABA shunt in the E2k67cells was indicated by increased 13C labeling of GABA compared to
the control cells. GABA concentration as determined by HPLC also
increased in the E2k67 cells compared to the control cells. The data are
consistent with enhanced glycolysis and GABA shunt in response to a
mild reduction in KGDHC [101]. The ﬁndings indicate that a mild
change in KGDHC activity can lead to large changes in metabolism.
The changes may allow maintenance of normal energy metabolism
but still make the cells less able to adapt to perturbations such as
occur with oxidants.
The levels of E2k protein modify the response to oxidative stress.
Subsequent experiments tested whether the response to an oxidant
challenge more closely paralleled the E2k protein levels or KGDHC
activity. Growth rates, increased DCF-detectable reactive oxygen
species, and cell death in response to added H2O2 are proportional to
E2k proteins, but not to complex activity. These results were not
predicted because subunits unique to KGDHC have never been mani-
pulated in mammalian cells. These results suggest that in addition to
its essential role in metabolism, the E2k component of KGDHC may
have other novel roles [100]. For example, the results are consistent
with the suggestion that a truncated gene product (MIRTD) of E2k
contributes to the biogenesis of the mitochondrial respiratory
complexes [79].
Alterations in E2k protein levels alter gene expression. Although
KGDHC activities are diminished in AD brains, the activities of MDH
are increased. To test the possibility that this is secondary to the
decline in KGDHC, MDH activity and message levels were determined
in cells with varying E2k protein levels. Activity of MDH is increased
with KGDHC deﬁciency but only in the E2k23 lines. Of the three lines
tested, these have the greatest decrease in E2k but nearly normal
KGDHC activities. In contrast to the increase in MDH activities, the
message levels of both cytosolic and mitochondrial MDH decline in
the E2k23 lines. H2O2 reduces KGDHC activities in cells, but increases
MDH activity and the message levels for both the mitochondrial and
cytosolic MDH—but only in the lines most deﬁcient in E2k. This raises
the possibility of a co-ordinate regulation of gene expression of the
TCA cycle [102]. The interaction of KGDHC with α-ketoglutarate
oxidases such as the HIF proly hydroxylases that have the same
substrate (ketoglutarate ) and same product (succinate) is not clear.
Thus, an increase in α-ketoglutarate due to impaired KGDHC may
increase HIF prolyl hydroxylases.
Treatment of puriﬁed KGDHC with oxidized glutathione (GSSG)
leads to glutathionylation of all three KGDHC subunits [103]. H2O2
converts reduced glutathione (GSH) to oxidized glutathione (GSSG),
which reacts with protein thiols [102]. Cellular glutathione level has
been manipulated in HEK cells by two means to determine whether
the level of E2k alters the effects of glutathione on KGDHC. Both
buthionine sulfoximine (BSO), which inhibits glutathione synthesis
without altering redox state, and H2O2 diminished glutathione to a
similar level after 24 h. However, H2O2, but not BSO, reduced KGDHC
activities, and the reduction was greater in the E2k-23 line with the
lowest E2k protein. These ﬁndings suggest that H2O2 moved gluta-
thione to the protein. These ﬁndings suggest that the E2k may
mediate diverse responses of KGDHC to oxidants [102]. When cardiac
mitochondria are challenged with H2O2, NADH production and
oxidative phosphorylation decline. Upon consumption of H2O2, mito-
chondrial function is restored. These alterations are due, in large part,
to reversible glutathionylation and inhibition of KGDHC [104]. In
addition, the differential response of KGDHC activities to BSO and
H2O2 together with the in vitro interaction of KGDHC with GSSG
suggests that glutathionylation is one possible mechanism underlying
oxidative stress-induced inhibition of the TCA cycle [102].
The ability of KGDHC to produce H2O2 suggests that inhibiting
KGDHC could be neuroprotective, while the diminished production of
NADHwould suggest that impairing KGDHC is damaging. As discussed
above, inhibiting KGDHC under normal conditions appears damaging.
However, if the cell is experiencing life threatening conditions,
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protection by impairing KGDHC in microglia. The KGDHC inhibitor
KMV (see above) dose-dependently reduced ROS production and LDH
release from a hypoxic microglial cell line [91]. KMV also reduced ROS
production and enhanced the cell viability following H2O2 but failed to
reduce the SIN-1 and sodium nitroprusside (SNP) toxicity. KMV also
reduced caspase-3 and -9 activation under stress. These results
suggest that KMV protects BV-2 cells from stress and acts by reducing
ROS production through inhibition of ROS production by KDGHC.
Inhibition of KGDHC can also be protective in neurons. KGDHC
inhibitors were added to glutamate poisoned neurons. Their subse-
quent inhibition of KGDHC decreases the mitochondrial potential
[105]. The production of O2
U− was detected by reaction with hydro-
ethidine. The distribution of the resulting ﬂuorescence of mt-DNA-
ethidiumcoincideswith that of themitochondrialmarkerMitotracker,
pointing to the mitochondrial site of the hydroethidine-detected ROS
in response to glutamate. The SP inhibitors described above inhibited
glutamate-induced ROS production by about 20–44%. The decreases in
neuronal ROS by speciﬁc inhibitors of KGDHC suggest that KGDHC is a
source of ROS in cultured neurons responding to glutamate. However,
at higher concentration the KGDHC inhibitor increased ROS produc-
tion compared with glutamate alone, presumably due to secondary
effects arising upon the strong KGDHC inhibition. This suggests that
different mechanisms are invoked at different concentrations. They
support the suggestion that inhibition of KGDHC ROS production can
protect against in vitro excitotoxicity [105].
8. Impairment of KGDHC in vivo induces oxidative stress and
compromises the ability of the brain to respond to other insults
Three different models test mechanistic interactions of KGHC in
neurodegeneration. They are presented from the most complex to the
one that only affects one enzyme. (1) thiamine deﬁciency (TD; i.e.,
vitamin B1 deﬁciency) which primarily affects KGDHC and transke-
tolase (a critical enzyme of the pentose shunt), although thiamine is
also a cofactor for PDHC, (2) E3+/–micewhich have reduced activities
of KGHC and PDHC and (3) E2k+/–mice, which have a primary deﬁcit
in only KGDHC. A comparison of the three models helps distinguish
critical variables that are necessary to cause particular deﬁcits.
8.1. Thiamine deﬁciency
Thiamine deﬁciency (TD) is amodel of neurodegeneration induced
bymild impairment of oxidative metabolism. Thiamine is required for
PDHC, KGDHCand transketolase. KGDHC is particularly sensitive to TD.
Further, KGDHC is more sensitive to TD in aged mice than young mice
[106]. TD produces a time-dependent, selective neuronal death in
speciﬁc thalamic brain regions. Loss of neurons and elevation in
markers of neurodegeneration are preceded or accompanied by
markers of oxidative stress that mimic the changes in brains from
ADbrain including: (1) changes inmicroglia including increased redox
active iron, (2) induction of nitric oxide synthase and heme
oxygenase-1, a marker of oxidative stress, and (3) altered processing
of amyloid precursor protein that exacerbates plaque formation in an
AD-like manner. Endothelial cells also show changes in early stages of
TD including induction of intracellular adhesion molecule-1 and of
endothelial NOS. Thus, the metabolic deﬁciency including the decline
in KGDHC is sufﬁcient to induce oxidative stress and an inﬂammatory
response [107]. Interestingly, TGase message levels are dramatically
increased (as much as 11 fold) in areas of brain damage in TD [108].
Whether the induction of TGase is secondary to the oxidative stress
induced by TD has not been tested. Nor has it been tested whether
impairing TGase would be protective. Mild impairment of oxidative
metabolism can induce a variety of physiological changes: oxidative
stress, increases in TGase message, an inﬂammatory response, altered
APP processing and neuronal death [107].8.2. E3 deﬁciency
The E3 component of KGDHC is a critical subunit common to
KGDHC and PDHC (as well as to the branched chain dehydrogenase
complex, which however has minimal enzymic activity compared
to the other two complexes). E3 is responsible for ROS production
by both complexes. The E3+/–mice do not show any generalized
neuron loss. They have increased oxidative stress as measured with
malondialdehyde. However, mice that are deﬁcient in E3 are
more vulnerable to brain damage induced by 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), malonate and 3-nitropropionic
acid (3-NP), toxins that have been proposed as models of PD
and HD, respectively. Administration of MPTP causes a greater
depletion of tyrosine hydroxylase-positive neurons in the substantia
nigra of E3+/–mice than in wild-type littermate controls. Striatal
lesion volumes produced by malonate and 3-NP are increased in
E3+/–mice [2]. Isolated brain mitochondria treated with 3-NP
show that both succinate-supported respiration and membrane
potential are suppressed to a greater extent in E3+/–mice. These
ﬁndings provide further evidence that mitochondrial defects may
contribute to the pathogenesis of neurodegenerative diseases [2].
Since E3 can be a source of free radicals in KGDHC and PDHC, a
reduction in E3 may be expected to decrease ROS. Indeed, mitochon-
dria isolated from these mice produce less ROS. However, in living
mice a reduction in the E3 component of KGDHC elevates free radical
production as shown by an increase in malondialdehyde in their
brains [2]. Further, the production of these ROS is exaggerated by
toxins that are used as models of PD and HD. These data provide direct
evidence that imbalance ROS metabolism occurs in animal models
with only mild reductions in glucose metabolism. Thus, both TD and
E3 deﬁciency enhance the production of oxidative stress. Further, the
production of these ROS is exaggerated by toxins that are used as
models of PD and HD. Thus, under the metabolic conditions that have
been studied in vivo, reductions in PDHC and KGDHC can initiate
oxidative stress.
8.3. Reduction of E2k in mice
To determine the consequences of diminished brain KGDHC acti-
vity, the dlst gene encoding the E2k subunit of KGDHC was disrupted.
This protein is unique to KGDHC. E2k+/–heterozygous mice
had lower message and protein levels for E2k, leading to reduced
brain KGDHC activity by about 50%. Behavioral assessment of adult
DLST+/–mice revealed abnormalities in a discriminative fear-
conditioning paradigm and in high-speed rotorod performance.
Spatial memory in a water maze task was unaltered. Neurons
cultured from DLST+/–mice have increased resting calcium levels.
Furthermore, oxidative stress as assessed by malondialdehyde is
increased in DLST+/–mice. Thus, a deﬁciency in KGDHC is by itself
sufﬁcient to induce oxidative stress in the brain [109].
9. Mild impairment of metabolism promotes pathologies related
to age-related neurodegenerative diseases
9.1. Abnormal mitochondrial function alters APP processing
Altered processing of amyloid precursor protein (APP) is promi-
nently associated with changes in AD, but it is likely altered in other
neurodegenerative diseases as well. Increased APP expression and
intracellular accumulation of its toxic fragments including the
carboxyl terminal fragment of APP have been associated with acute
neuronal death. APP C-terminal and β-amyloid domains occur in rat
substantia nigra pars reticulata neurons targeted for delayed degen-
eration following a neurotoxic striatal lesion [110]. These ﬁndings
suggest that intranuclear APPC-terminal fragments (CTF) play a role in
genomic events contributing to delayed neuron degeneration [110].
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During TD, CTF of APP appears in the nuclei of neurons that will die
5–6 days before neuron death [111]. Thus, very mild interruptions of
metabolism and of KGDHC can lead to altered APP processing leading
to accumulation of CTF of APP in the nuclei of neurons that will die.
Mild impairment of energy metabolism can also lead to the
formation of Alzheimer-like plaques. In Tg19959 transgenic mice over
expressing a double mutant form of APP, TD exacerbates amyloid
plaque pathology, and enlarges the area occupied by plaques by 50%
in cortex and by 200% in both hippocampus and thalamus. TD
increases Aβ (1–42) levels by about three fold, beta-CTF (C99) levels
by 33% and β-secretase (BACE1) protein levels by 43%. Thus, TD
induces plaque formation throughout the brain even though neuron
loss is restricted to a small region [112].
Alterations of metabolic/oxidative activity modify APP processing
in a variety of different models. Genetic ablation of inducible nitric
oxide synthase protects against plaque formation in mice [113].
Insulin, 2-deoxyglucose, 3-nitropropionic acid, and kainic acid induce
acute energy inhibition, and simultaneously induce the BACE enzyme
which cleaves APP [114]. Cerebral Aβ1–40 levels in plaque bearing
mice increase to approximately 200% of control at seven days after
treatment, demonstrating that energy inhibition can be amyloido-
genic [114]. Energy deprivation induces phosphorylation of the
translation initiation factor eIF2α to eIF2α-P, which increases the
translation of BACE1 [115]. These results strongly suggest that eIF2α
phosphorylation increases BACE1 levels and causes Aβ overproduc-
tion, which could be an early, initiating molecular mechanism in
sporadic AD [115]. Thus, these studies demonstrate that impairing
energy metabolism can promote plaque formation.
9.2. Abnormal mitochondrial function can also lead to tangle formation
A reduction in mitochondrial function can also lead to tangle for-
mation. Tangles are hyperphosphorylated tau proteins, and a hallmark
of typical pathology in AD brains. They also occur in brains from
patients with Wernicke–Korsakoff syndrome (i.e., human thiamine
deﬁciency) [116]. Insulin deﬁciency and diabetes causes a mild hyper-
phosphorylation of tau at early stages, and at later stages massive
hyperphosphorylation of tau occurs. However, neither mild nor
massive tau phosphorylation induced tau aggregation in mice or
rats, i.e., true tangles [117]. Rotenone, an inhibitor of electron trans-
port, causes loss of neurons in the substantia nigra and in the striatum.
Spherical deposits of alpha-synuclein,which accumulates in Parkinson
disease, are observed in a few cells, but cells with abnormal cyto-
plasmic accumulations of tau immunoreactivity are signiﬁcantly more
numerous in the striatum after rotenone [118] or annonacin, a natural
complex I inhibitor [119], treatment. Many tau+ cell bodies also stain
positively for thioﬂavin S (which stains Alzheimer plaques and tangles),
for nitrotyrosine and for ubiquitin [120]. The data suggest that chronic
respiratory chain dysfunction might trigger a form of neurodegenera-
tion in which accumulation of hyperphosphorylated tau protein
predominates over deposits of α-synuclein [118]. SOD2 deﬁciency
which increases ROS also increases tau phosphorylation [121].
9.3. Abnormal energy metabolism and oxidative stress also alter cellular
calcium
Glucose metabolism and cellular calcium are closely linked.
Mitochondrial calcium uptake is diminished in mitochondria from
AD ﬁbroblasts [122]. The changes in calcium regulation in mitochon-
dria from E2k deﬁcientmice are consistentwith alteredmitochondrial
buffering. Endoplasmic reticulum (ER) calcium is a major calcium
store within the cell, ER calcium is increased in cells bearing AD
causing presenilin-1 mutations [123]. ER calcium is also increased in
non-genetic forms of AD. ER calcium is also sensitive to oxidants. A
screen of a variety of times and dosages of revealed that speciﬁcoxidants can alter calcium in an AD-like manner. These oxidant-
induced changes can be blocked by speciﬁc antioxidants. The anti-
oxidants that blocked the effects the effects on ER calcium also
ameliorated the deﬁcits in ER calcium in cells from AD patients [124].
9.4. KGDHC changes with aging
The most important factor for developing age-related neurode-
generative diseases is aging. One possibility for a role of KGDHC in age
related neurodegeneration is that a factor with agingmaking the brain
vulnerable with age. In mice, the baseline activity of brain KGDHC
does not changewith age, but with increased age it does becomemore
sensitive to other metabolic insults such as thiamine deﬁciency [106].
KGDHC activity also diminishes with age in heart, and the number of
hydroxynoneal (HNE) adducts is increased [125]. Hearts from old rats
exhibit signiﬁcantly higher HNE-modiﬁed mitochondrial proteins
when compared with those from young rats. The protein most
markedly modiﬁed by HNE with age is the E2k component of KGDHC
[125]. Replicative life span in Saccharomyces cerevisiae is increased by
glucose limitation and by augmented NAD+. The increased life span
due to glucose limitation is related to diminished mitochondrial ROS
production. The data indicate that E3 is an important source of
glucose-mediated preventable mitochondrial ROS production. The
results substantiate the concept that E3 is an important and novel
source of ROS limiting life span [126].
9.5. Neurogenesis is impaired by reductions in KGDHC
Although the precise role of neurogenesis in the adult brain is
unknown, one interpretation is that it permits the brain to respond to
insults. Thus, reduction in neurogenesis would make the brain less
able to respond [127]. Mitochondrial dysfunction can inﬂuence the
number of neural progenitor cells in the hippocampus of adult mice
[109].Neurogenesis is impaired in three models of impaired TCA cycle
enzymes including E2k+/–, E3+/– [109] and thiamine deﬁciency
[127]. Adult brain neurogenesis was assessed using immunohisto-
chemistry for the immature neuron markers, doublecortin (Dcx) and
polysialic acid-neural cell adhesion molecule, as well as a marker for
proliferation, proliferating cell nuclear antigen (PCNA). Both E3 and
E2k-deﬁcient mice showed reduced Dcx-positive neuroblasts in the
subgranular zone (SGZ) of the hippocampal dentate gyrus compared
with wild-type mice. PCNA staining reveals decreased proliferation in
the SGZ of E2k-deﬁcient mice. An analogous pattern of change was
observed in thiamine-deﬁcient mice [127].
9.6. Mitochondrial dynamics
Extensive evidence implicates mitochondrial dynamics in neuro-
degenerative diseases. Whether these changes lead or follow the
changes in mitochondrial function described in this review is
unknown. These dynamic processes include transport of mitochon-
dria down axons and dendrites as well as mitochondrial ﬁssion and
fusion. Axonal transport is energy dependent and the movement of
mitochondria can be selectively impaired by glutamate, zinc, rotenone
or uncouplers [128]. Thus, any interruption of energymetabolism (i.e.,
a loss of KGDHC activity) may diminish transport. The resulting
diminished mitochondrial function in the nerve ending would likely
diminish synaptic function. Similarly, a balance of fusion and ﬁssion is
necessary for normal mitochondrial and neuronal function. Changes
in ﬁssion/fusion alter mitochondrial function and vice versa.
Disruption of the mitochondrial ﬁssion and fusion equilibrium lead
to neurodegeneration [129]. Genetic mutations in fusion proteins
cause neuropathy. When genetic defects lead to lack of fusion, the
enzymes encoded by the mitochondrial (mt)DNA are most affected,
whereas the expression of nuclear DNA–encoded enzymes increase,
apparently to compensate for the mitochondrial dysfunction. The
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sion are lost in the neuronal terminals more than in the cell body
[129,130]. Dominant optic atrophy is caused bymutations in the OPA1
gene, which encodes a dynamin-related GTPase required for mito-
chondrial fusion [131]. In Drosophila, increased mitochondrial ﬁssion
occurs in PDmodels, such asmutations in PINK1, and proteins that are
mutant in genetic forms of PD promote ﬁssion, and their inhibition
leads to excessive fusion [132]. In mammalian cells, PINK1 mutants or
knockdown promotes excessive ﬁssion [133–135]. Parkin and PINK2
function in a pathway in which defective mitochondria are targeted
for autophagy [136]. Mutant huntingtin alters mitochondrial mor-
phology and dynamics. Both rotenone and β-amyloid initiate mito-
chondrial ﬁssion. Mitochondrial ﬁssion is an early event in ischemic
stroke and diabetic neuropathies [137]. Recent studies show that APP,
through Aβ production, causes an imbalance of mitochondrial ﬁssion/
fusion that results in mitochondrial fragmentation and abnormal
distribution, which contributes to mitochondrial and neuronal dys-
function [138]. In AD brains, mitochondria are distributed away from
axons in pyramidal neurons, and this is replicated in cultured neurons
using oligomeric Aβ [139,140]. As described in other sections of this
review, mild impairment of oxidative metabolism can lead to
overproduction of Aβ. Thus, mild impairment of oxidativemetabolism
can lead to increased Aβ which can imbalance fusion/ﬁssion. Thus,
precedent exists that suggests alteration in fusion/ﬁssion could lead
to alterations in mitochondrial proteins and that alterations in energy
metabolism can cause changes in fusion/ﬁssion. Together they would
form a cascade of events to promote neurodegeneration.
10. Therapeutic approaches
The goal of these studies is to develop new therapeutic strategies.
The data reviewed above suggest several innovative approaches.
10.1. Bypass the metabolic block
Since the degree of cognitive deterioration in AD correlates to the
reduction in cerebral metabolic rate, this is a reasonable therapeutic
target. An attempt to treat this abnormality in AD patients is based on
feeding the patients glucose and malate to bypass the diminished
activities of PDHC and KGDHC. In addition, the antioxidant resveratrol
is included. Encouraging results of a preliminary double-blind clinical
trial do not allow conﬁdent conclusions but do support the need for
more intensive examination of this approach to AD treatment [141].
10.2. Reactivate KGDHC
KGDHC is diminished in brains of patients that died with neuro-
degenerative diseases. The lack of change in protein levels suggest
that this is related to a post-translational modiﬁcation. Thus, reversal
of the modiﬁcation should be beneﬁcial. Glutathionylation of KGDHC
due to H2O2 reverses when H2O2 is diminished [104]. Nitration of
isolated KGDHC can also be reversed by glutathione [103]. The
inactivation of KGDHC in cells by 4-hydroxy-2-nonenal can be pro-
tected against by DL-lipoamide, DL-lipoic acid, reduced glutathione and
cysteine [142]. Prolonged treatment with trolox (a vitamin E like
compound) increases KGDHC by three fold [124]. In vivo treatment
with particular lipoic acid derivatives can increase heart KGDHC two
to three fold [143] . Although reversing the inactivation of one enzyme
may seem like a too focused approach, one should remember that
even relatively small increases in the activity of enzymes involved in a
number of inborn errors of metabolism have been associated with
clinically signiﬁcant beneﬁts. Furthermore, it is likely that compounds
that reactivate KGDHC may also reactivate other processes that have
been inactivated by similar mechanisms. For example, the same con-
ditions that inactivate KGDHC alter endoplasmic reticulum calcium in
a manner that is reminiscent of AD [124].10.3. Inhibit TGase activity
Numerous papers try to block the actions of TGase in order to treat
multiple disorders including skin and gastrointestinal disorders. The
inhibitors of TGase are generally directed to blocking the crosslinking.
The inhibitors would act to block the crosslinking of enzymes such
KGDHC and aconitase, and also to alleviate the inhibition of trans-
cription. The compound used the most with the CNS is cystamine.
Treatment in R6/2 transgenic HD mice, using the transglutaminase
inhibitor cystamine, signiﬁcantly extends survival, improves body
weight and motor performance, and delays the neuropathological
sequelae [54,55]. Free N[Sigma]-([gamma]-L-glutamyl)-L-lysine
(GGEL), a speciﬁc biochemical marker of TGase activity, is markedly
elevated in the neocortex and caudate nucleus in HD patients. TGase
activity and GGEL levels are signiﬁcantly altered in HD mice. Both
TGase and GGEL immunoreactivities colocalized to huntingtin
aggregates. Cystamine treatment normalized transglutaminase and
GGEL levels in R6/2 mice. These ﬁndings are consistent with the
hypothesis that transglutaminase activity may play a role in the
pathogenesis of HD, and they identify cystamine as a potential
therapeutic strategy for treating HD patients [54,55]. However, the
speciﬁcity of cystamine is questionable, so the studies need to be
replicated with more speciﬁc TGase inhibitors that enter the brain.
Rather than being a direct inhibitor of TGase in brain, cystamine
may provide an alternative substrate for TGase. Cystamine [[beta]-
mercaptoethanolamine (MEA) disulﬁde] is reduced within cells to
MEA which is largely responsible for the in vivo effects of its disulﬁde
precursor. The amine group of MEA acts as a TGase substrate resulting
in the formation of N[beta]-([gamma]-L-glutamyl)-MEA bonds. The
formation of such bonds would compete with the generation of other
TG-catalyzed reactions that may contribute to neurodegeneration
such as polyamination, protein cross-linking, deamination and the
covalent attachment of ceramide to proteins. Structure-function
studies also indicated that the mercapto group of MEA signiﬁcantly
inﬂuences the substrate behavior of this compound [144]. Whether
the more speciﬁc inhibitor of TGase, ZDON, that overcomes transcrip-
tional inhibition associated with mutant huntingtin can be beneﬁcial
in mice or humans is unknown [51].
10.4. Prevent upregulation of TGase
The ability of glutathione to prevent glutamate-evoked TGase
upregulation was tested in astrocyte cultures. A 24 h exposure to
glutamate caused a dose-dependent depletion of glutathione intra-
cellular content and increased the ROS production. Pre-incubation
with glutathione ethyl ester or cysteamine recovered oxidative status
andwas effective in signiﬁcantly reducing glutamate-increased TGase.
These data suggest that TGase upregulation may be part of a bio-
chemical response to oxidative stress induced by a prolonged
exposure of astrocyte cultures to glutamate [43]. Thus, the available
data suggest that both the KGDHC deﬁcit and the induction of
transglutaminase increase in neurodegenerative diseases can be
“treated” with glutathione. One way to increase glutathione is by
administration of tri-terpenoids, or other compounds, which activate
NrF2/ARE pathway which activates the enzymes involved in gluta-
thione synthesis [145].
10.5. Act on redox sensitive transcription factors
Chronic exposure to ROS in neurodegenerative diseases likely
activates cascades of genes. Even if initially protective, prolonged
activation may be damaging. Thus, therapeutic approaches based on
modulation of these gene cascades may lead to effective therapies.
Genes involved in several pathways including antioxidant defense,
detoxiﬁcation, inﬂammation, etc. are induced in response to oxidative
stress in neurodegeneration. However, genes that are associated
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tion, are mostly down-regulated. Redox sensitive transcription factors
such as activator protein-1 (AP-1), nuclear factor κB (NF-κB),
speciﬁcity protein-1 and hypoxia-inducible factor (HIF) are important
in redox-dependent gene regulation. PPARγ co-activator (PGC-1α) is
a co-activator of several transcription factors and is a potent stimu-
lator of mitochondrial biogenesis and respiration. Down-regulated
expression of PGC-1α has been implicated in HD and in several HD
animal models [59–61]. Its role in regulation of ROS metabolism
makes it a potential candidate player between ROS, mitochondria and
neurodegenerative diseases [146]. Potential therapeutic strategies
based on the updated understandings of redox state-dependent gene
regulation may be productive [147].
Therapies normally associated with antioxidant or energy metab-
olism may work by more general gene mechanisms. For example,
results show a protective effect of two mitochondrial antioxidant/
nutrients, R-αlipoic acid and acetyl-L-carnitine in a chronic rotenone-
induced cellular model of PD. When combined, lipoic acid and
acetylcarnitine work at 100- to 1000-fold lower concentrations than
they did individually. The combined pretreatment increases mito-
chondrial biogenesis and decreases production of ROS reactive oxygen
species through the up-regulation of the peroxisome proliferator-
activated receptor-γ (PGC-1α)—a possible underlying mechanism
[148].
Experiments with HIF1-1 provide a speciﬁc example of this
approach. The transcription factor hypoxia-inducible factor-1 (HIF1-1)
mediates the activation of a large cassette of genes involved in
adaptation to hypoxia in surviving neurons after stroke. Pharmacolog-
ical or molecular approaches that inhibit HIF prolyl 4 hydroxylases lead
to profound sparing of brain tissue and enhanced recovery of function.
The strategy appears to involve HIF-dependent and HIF-independent
pathways and more than 70 genes and proteins activated transcrip-
tionally and post-transcriptionally [149]. One of the genes activated by
HIF is TGase [150], and TGase regulates HIF [56].
11. Conclusion
A surprisingly large number of features of age-related neurode-
generative diseases can be accounted for by changes in KGDHC, TGase,
oxidative stress and calcium (Fig. 4). Therapeutic approaches that
ameliorate these deﬁcits are likely to be therapeutically useful.Fig. 4. Interaction of TGase, oxidative stress, calcium lead to abnormal mitochondrial
function and diminished ability to adapt.Acknowledgements
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